Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Pertuzumab

Klassificering: B

Preparat: Perjeta

ATC kod: L01XC13

Substanser: pertuzumab

Sammanfattning

Pertuzumab används vid vissa typer av HER2-positiv bröstcancer och därför nästan enbart hos kvinnor. Relevanta analyser eller studier om könsskillnader saknas därför.

Additional information

Pertuzumab inhibits ligand-initiated intracellular signaling and mediates antibody-dependent cell-mediated cytotoxicity and is used in combination with trastuzumab and chemotherapy for some types of HER2-positive breast cancer [1,2].

Pharmacokinetics and dosing

No difference in dosing between men and women is recommended by the pharmaceutical company [1, 2].

Effects

As the indication for pertuzumab is HER2-positive breast cancer, a disease affecting mostly women, most studies include almost only women [3-5]. Thus, controlled studies with a relevant analysis of differences between men and women regarding pharmacokinetics, effects, or safety of pertuzumab are lacking.

Adverse effects

See above.

Reproductive health issues

Data is lacking but pertuzumab, like most other anti-cancer drugs, is not considered compatible with pregnancy. It is recommended that women of childbearing potential use contraceptives during and for 7 months after use of pertuzumab [1, 2]. The pharmacautical compnay reports that limited data from toxicity studies indicate that pertuzumab may affect the male reproductive system [1]. Regarding teratogenic birth defects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Läkemedel innehållande pertuzumab (ATC-kod L01XC13) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata.

Uppdaterat: 2019-07-16

Litteratursökningsdatum: 2019-05-28

Referenser

  1. US National Library of Medicine. Perjeta (pertuzumab) DailyMed. DailyMed [www]. [updated 2018-12-26, cited 2019-05-28]. länk
  2. Läkemedelsindustriföreningen (LIF). Perjeta (pertuzumab) FASS. Fassse [www]. [updated 2019-03-28, cited 2019-05-28]. länk
  3. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115-126. PubMed
  4. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131. PubMed
  5. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19. PubMed
  6. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.] länk

Författare: Mia von Euler

Faktagranskat av: Karin Schenck-Gustafsson

Godkänt av: Karin Schenck-Gustafsson